ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

The NIFTY MIDCAP 150's movements reflect ongoing market dynamics, with Global Health, JSW Infra, and GlaxoSmithKline ...

GlaxoSmithKline Pharmaceuticals Ltd. reported a 36% increase in consolidated net profit to Rs 263 crore for the quarter ended ...

GlaxoSmithKline Pharmaceuticals, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹2827.05. The stock has experienced fluctuations ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/16/25, Coca-Cola Europacific Partners plc (Symbol: CCEP), Smurfit Westrock plc (Symbol: SW), and Glaxosmithkline plc (Symbol ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...